Where can I buy shares of bngo?
· Bionano Genomics' stock was trading at $0.5770 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BNGO shares have increased by 170.4% and is now trading at $1.56. View which stocks have been most impacted by COVID-19.
What is the bngo stock price prediction for 2026-06-15?
Bionano Genomics prices $200 mln underwritten stock offering at discount of $6 a share
How often do you update the bngo stock projections?
· BNGO Bionano Genomics Inc — Stock Price and Discussion | Stocktwits. Bionano Genomics Inc NASDAQ Updated May 13, 2022 9:45 PM. BNGO 1.62 0.21 (14.89%)
What is the price prediction for BioNano Genomics Inc (bngo) stock?
braydenboyko Dec 20, 2021. NASDAQ:BNGO BNGO has seen a steady decline over the last 8 months, you can read my past articles for the reasoning for this. I believe we have now found our fair value of this company. the stock has been steadily holding the …
See more
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.50% and 5.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to …
How much does BNGO cost?
Predicted Opening Price for BioNano Genomics Inc. of Thursday, March 24, 2022Fair opening price March 24, 2022Current price$2.40$2.40 (Undervalued)
Is BNGO a good stock to buy now?
Right now, BNGO stock trades at around the same price as it did before its massive break out to begin 2021. In turn, with this incredible performance last year and its massive potential in genomic analysis, it could be a multi-bagger in the future.
Is BNGO expected to rise?
Bionano Genomics Inc (NASDAQ:BNGO) The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +395.36% increase from the last price of 1.62.
Is BNGO a US stock?
BNGO | Bionano Genomics Inc. Stock Overview (U.S.: Nasdaq) | Barron's.
Should I sell or hold BNGO?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Who is buying BNGO stock?
Top 10 Owners of Bionano Genomics IncStockholderStakeShares ownedBlackRock Fund Advisors5.67%16,416,245The Vanguard Group, Inc.5.23%15,158,122SSgA Funds Management, Inc.2.49%7,198,880Geode Capital Management LLC1.52%4,392,7346 more rows
What kind of stock is BNGO?
Key DataLabelValueSectorCapital GoodsIndustryBiotechnology: Laboratory Analytical Instruments1 Year Target$7.50Today's High/Low$1.65/$1.4613 more rows
What type of stock is BNGO?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space.
What does BNGO company do?
The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
How many shares does BNGO have?
Share StatisticsAvg Vol (3 month) 37.41MShares Outstanding 5289.7MImplied Shares Outstanding 6N/AFloat 8283.64M% Held by Insiders 11.89%7 more rows
When did BNGO IPO?
August 21, 2018The units are scheduled to begin trading on The Nasdaq Capital Market under the ticker symbol “BNGOU” on August 21, 2018, and the offering is expected to close on August 23, 2018, subject to customary closing conditions.
Is BNGO in Russell?
(Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstitution.
Is Bionano Genomics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 3...
How has Bionano Genomics' stock been impacted by Coronavirus (COVID-19)?
Bionano Genomics' stock was trading at $0.5770 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Healt...
When is Bionano Genomics' next earnings date?
Bionano Genomics is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for Biona...
How were Bionano Genomics' earnings last quarter?
Bionano Genomics, Inc. (NASDAQ:BNGO) announced its quarterly earnings data on Tuesday, March, 1st. The company reported ($0.08) earnings per share...
What guidance has Bionano Genomics issued on next quarter's earnings?
Bionano Genomics updated its FY 2022 earnings guidance on Tuesday, March, 15th. The company provided earnings per share guidance of for the period....
What price target have analysts set for BNGO?
3 brokerages have issued 1-year target prices for Bionano Genomics' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate...
Who are Bionano Genomics' key executives?
Bionano Genomics' management team includes the following people: Robert Erik Holmlin , President, CEO, Secretary & Director Mark Oldakowski , Ch...
What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO?
10 employees have rated Bionano Genomics CEO R. Erik Holmlin on Glassdoor.com . R. Erik Holmlin has an approval rating of 73% among Bionano Genomi...
Who are some of Bionano Genomics' key competitors?
Some companies that are related to Bionano Genomics include HORIBA (HRIBF) , Pacific Biosciences of California (PACB) , Olink Holding AB (publ)...
What is the BNGO symbol?
How much does Bionano generate?
Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."
What is the P/E ratio of Bionano?
Bionano Genomics has a market capitalization of $1.72 billion and generates $8.50 million in revenue each year . The company earns $-41,110,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.
Is Bionano Genomics a buy?
The P/E ratio of Bionano Genomics is -20.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is Bionano Genomics?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Does Bionano pay dividends?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Recently Viewed Tickers
Bionano Genomics does not currently pay a dividend.
Bionano Genomics Inc
Visit a quote page and your recently viewed tickers will be displayed here.
What is BNGO in 2021?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space.
Who is the CEO of Bionano?
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study by Johns Hopkins University in the Journal of Clinical & Anatomic Pathology outlining a stepwise approach to adoption of OGM for cancer analysis in the cytogenetics lab. “This publication is by an outstanding team at John
Is Bionano a loss?
Leading the call today is Dr. Erik Holmlin, CEO of Bionano. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
When will BNGO report earnings?
Bionano (BNGO) might have reported a wider loss than expected in Q3, but that factor is of less importance to Oppenheimer’s Kevin DeGeeter. The life sciences company reported a net loss of $20.75 million, a 92% increase on the same period last year. However, DeGeeter believes the company surpassed expectations on the three most important metrics. First off, for the 6th consecutive quarter, Bionano posted a beat on the top-line, with revenue increasing by 112% year-over-year to $4.7 million vs. t
What is BNGO in genomics?
As BNGO looks to complete its corrective ABC pattern, you can use that information to plan your entry strategy. The company will report earnings on March 9, 2021, so look for volatility around that date.
Where is Bionano headquartered?
BNGO is a leader in the digital cytogenetics niche. Its genome-imaging system, Saphyr, is arguably the most advanced hardware of its class today. Meanwhile, the global genomics market is expected to increase from $20 billion today to $80 billion by 2027.
How do retail investors buy stocks?
Founded in 2003, Bionano Genomics is currently headquartered in San Diego, California. A public company since 2018, BNGO has a market cap of $1.7 billion and employs 127 employees.
Is BNGO a volatile company?
Retail investors like yourself are buying stocks through the brokers. Brokers serve as licensed intermediaries that process your orders on the financial markets. Opening an account is a safe, streamlined process and it enables you to invest through your computer or even your phone.
